Division of Cancer Tratment and DIagnosis- Operational Task Order

癌症治疗和诊断科-操作任务顺序

• 批准号: 10273220
• 负责人: LEONARD FREEDMAN
• 金额: $ 6338.13万
• 依托单位: LEIDOS BIOMEDICAL RESEARCH, INC.
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-08-31 至 2021-08-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10273220
• 关键词: Antineoplastic Agents; Archives; Biological; Biological Assay; Biological Markers; Biological Products; Clinic; Clinical; Clinical Trials; Collaborations; Contracts; Correlative Study; Cyclic GMP; Data Science; Development; Diagnosis; Diagnostic; Diagnostic tests; Discipline of Nursing; Division of Cancer Treatment and Diagnosis; Drug Kinetics; Evaluation; Funding; Genomics; Image; Immunotherapy; In Vitro; Informatics; Information Systems; Laboratories; Libraries; Malignant Neoplasms; Medical; Molecular; Nanotechnology; Natural Products; New Agents; Operative Surgical Procedures; Patients; Performance; Pharmaceutical Preparations; Pharmacology; Pre-Clinical Model; Precision medicine trial; Production; Radiation; Radiochemistry; Radiopharmaceuticals; Research; Services; Technology; Testing; Therapeutic Intervention; Toxicology; Translational Research; United States National Institutes of Health; Work; Xenograft procedure; assay development; biobank; clinical center; drug development; drug discovery; drug production; high throughput screening; image archival system; in vivo; novel diagnostics; novel therapeutic intervention; pharmacodynamic biomarker; programs; repository; tumor

The Division of Cancer Treatment and Diagnosis (DCTD) supports the development of novel diagnostic and therapeutic approaches for cancer by expediting the initial and subsequent large-scale testing of new agents, biomarkers, imaging tests, and other diagnostic and therapeutic interventions (radiation, surgery, immunotherapy) in patients. Within DCTD, eight major programs and a patient clinic work together to bring unique molecules, diagnostic tests, and therapeutic interventions from the laboratory bench to the patient bedside. Activities supported under this contract include: isolation and evaluation of natural products; molecular pharmacology; high-throughput screening of compound libraries; pharmacodynamic marker and pharmacokinetic assay development and utilization in clinical trials; drug toxicology research; information systems, technologies, and data science; drug discovery; radiochemistry and radioactive drug production; archival of clinical trial images, in vitro and in vivo translational research; repository support for natural products, patient-derived xenografts, tumors and biologic anti-cancer agents; a biopharmaceutical production facility; medical writers; nursing support services for clinical trials performed in the NIH Clinical Center, correlative studies in collaboration with biopharmaceutical companies; support for precision medicine trials; advanced genomics capabilities supporting tumor evaluation in pre-clinical models and clinical trials; patient biorepositories for NCI-funded clinical trials; nanotechnology characterization and evaluation.

癌症治疗和诊断（DCTD）的分裂通过加快对患者的新药物，生物标志物，成像测试以及其他诊断和治疗性干预措施（放射，手术，免疫疗法）的初始和随后的大规模测试来加快新型诊断和治疗方法的新诊断和治疗方法。 在DCTD中，八个主要计划和一个患者诊所共同努力，从实验室长凳到患者的床边带来独特的分子，诊断测试和治疗干预措施。 根据本合同支持的活动包括：天然产品的隔离和评估；分子药理学；复合库的高通量筛选；临床试验中的药效标记和药代动力学测定和利用；药物毒理学研究；信息系统，技术和数据科学；毒品发现；放射化学和放射性药物生产；临床试验图像的档案，体外和体内翻译研究；天然产物，患者衍生的异种移植物，肿瘤和生物抗癌剂的存储库支持；生物制药生产设施；医学作家；在NIH临床中心进行的临床试验的护理支持服务，与生物制药公司合作的相关研究；支持精密医学试验；在临床前模型和临床试验中支持肿瘤评估的高级基因组学能力；用于NCI资助的临床试验的患者生物疗法；纳米技术表征和评估。